81864-14-4

Usage

Uses

Used in Pharmaceutical Research and Development:
N-(6-Nitro-1,3-benzodioxol-5-yl)acetamide is utilized as a building block or intermediate in the synthesis of new drugs and therapeutic agents. Its unique structure and functional groups make it a valuable component in the development of pharmaceuticals with novel mechanisms of action and therapeutic potential.
Used in Agrochemical Production:
N-(6-Nitro-1,3-benzodioxol-5-yl)acetamide also serves as an intermediate in the production of various agrochemicals, contributing to the development of new pesticides, herbicides, and other agricultural chemicals that can improve crop yield and protect plants from pests and diseases.
Used in Academic and Industrial Research:
N-(6-Nitro-1,3-benzodioxol-5-yl)acetamide is employed in research settings for the investigation of chemical reactions and processes. Its unique structure allows researchers to explore new synthetic pathways, reaction mechanisms, and the development of innovative chemical methodologies.

Upstream product

• 108-24-7 acetic anhydride 
• 13067-19-1 3,4-methylenedioxyacetanilide 
• 14268-66-7 benzo[1,3]dioxolo-5-ylamine 

Downstream Products

• 64993-07-3 2-amino-4,5-methylenedioxy-1-nitrobenzene 

Relevant academic research and scientific papers

A Novel Difluoroacetic Acid Derivatives Compound, and Composition Comprising the Same

The present invention relates to a novel difluoroacetic acid derivative compound and a composition for various uses containing the same, wherein the difluoroacetic acid derivative compound can not only act as an agonist activating one among PPARandalpha;, andbeta; or andgamma;, but also can exhibit double efficacy or triple efficacy. Therefore, the difluoroacetic acid derivative compound can more effectively prevent, alleviate or treat metabolic diseases in which PPARs involves, and further exhibits whitening and wrinkle alleviation activity, and anti-inflammatory and antioxidant effects, thereby being able to be usefully utilized as various compositions.COPYRIGHT KIPO 2020

Tricyclic [1,2,4]triazine 1,4-dioxides as hypoxia selective cytotoxins

A series of novel tricyclic triazine-di-N-oxides (TTOs) related to tirapazamine have been designed and prepared. A wide range of structural arrangements with cycloalkyl, oxygen-, and nitrogen-containing saturated rings fused to the triazine core, coupled with various side chains linked to either hemisphere, resulted in TTO analogues that displayed hypoxia-selective cytotoxicity in vitro. Optimal rates of hypoxic metabolism and tissue diffusion coefficients were achieved with fused cycloalkyl rings in combination with both the 3-aminoalkyl or 3-alkyl substituents linked to weakly basic soluble amines. The selection was further refined using pharmacokinetic/pharmacodynamic model predictions of the in vivo hypoxic potency (AUCreq) and selectivity (HCD) with 12 TTO analogues predicted to be active in vivo, subject to the achievement of adequate plasma pharmacokinetics.

TRICYCLIC 1,2,4-TRIAZINE OXIDES AND COMPOSITIONS THEREFROM FOR THERAPEUTIC USE IN CANCER TREATMENTS

The invention relates to novel tricyclic 1,2,4-triazine-1-oxides and novel tricyclic 1,2,4-triazine-1,4-dioxides of formula: (I); and to related analogues, to their preparation, and to their use as hypoxia-selective drugs and radiosensitizers for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs.

Imidazole derivatives

Tricyclic imidazole derivatives of the formula STR1 wherein R1 is 2-pyridyl optionally substituted by lower alkyl or lower alkoxy, n is the integer 0 or 1, R2 is hydrogen or lower alkyl, R3 and R4, independently, are hydrogen or lower alkyl, A is a group of the formula STR2 m is the integer 2 or 3, R5, R6, R7 and R8, independently, are hydrogen or lower alkyl, and R9 is hydrogen and R10 is hydrogen or lower alkyl or R9 and R10 taken together are oxo, provided that at least one of R3 and R4 is lower alkyl when A is a group of the formula and their pharmaceutically acceptable acid addition salts. The compounds of formula I inhibit gastric acid secretion and prevent the formation of gastric ulcers.